Triglycerides Medium Chain Formula
Recommended MetabolicRestrictedNot applicable line 💬 consumer voice
Dietary management of conditions requiring a source of medium chain triglycerides.
9
Submissions
1 resub
2014–20
On the record
—
ICER range
Not modelled
Cost basis
Decisions on record
- Meeting Jul 2025 Recommended Dietary management requiring medium chain triglycerides source no PSD
- Meeting Jul 2020 Recommended Dietary management of conditions requiring a source of medium chain triglycerides
- Meeting Mar 2020 Recommended Dietary management of conditions requiring a source of medium chain triglycerides
- Meeting Mar 2020 Not recommended Dietary management of conditions requiring a source of medium chain triglycerides
- Meeting Jul 2018 Recommended Chylous ascites; Chylothorax; Fat malabsorption; Hyperlipoproteinanaemia type 1; Long chain fatty acid oxidation disorders
- Meeting Jul 2017 Recommended Dietary management of conditions requiring a source of medium chain triglycerides
- Meeting Nov 2016 Recommended Dietary management of conditions requiring a source of medium chain triglycerides no PSD
- Meeting Jul 2015 Recommended Medicinal food no PSD
3 earlier decisions
- Mar 2015 Recommended Medicinal food
- Jul 2014 Recommended Powder for oral liquid, 400 g Peptamen Junior® Nestle Health Science New listing (Minor submission) Medicinal food Restricted Benefit listing for fat malabsorption due to liver disease, short gut syndrome, cystic fibrosis and gastrointestinal disorders.
- Sep 2001 Recommended A food supplement for inborn errors of metabolism no PSD
Access path
- Jul 2014Recommended · restricted
vs Monogen
- Mar 2015Recommended · restricted
Comparator changed: Monogen → Peptamen Junior
- Nov 2015Recommended
Evidence: Cost-minimisation → Other
- Mar 2016Recommended · restricted
Evidence: Other → Cost-minimisation
- Jul 2017Recommended
- Jul 2018Recommended
Listing: Restricted → Authority Required
- Mar 2020Not recommended
Inadequate clinical evidence to support broadening current listing; population definition unclear and could lead to…
- ↻ resubmittedMar 2020Recommended · restricted
Evidence: Cost-minimisation → Single-arm
- Jul 2020Recommended · restricted
- PBS listing · Restricted
RecommendedDeferredNot recommended
From the public summary
PBAC outcome
6.1 The PBAC recommended continuing the Restricted Benefit listing of triglycerides medium chain formula, Monogen, for the dietary management of conditions requiring 3PSD · Jul 2020
6.2 The PBAC noted that the NPWP was not concerned with the manganese levels being lower than the Australian AI levels, as adequate levels could be reached with the consumption of drinking water, vegetables and cereals.PSD · Jul 2020
Economic analysis
5.6 The submission requested the same AEMP as Peptamen Junior on the private market and the current PBS listing for Peptamen Junior, of $36.55 per 400 g tin.PSD · Mar 2020
5.7 The submission claimed that it used a conservative approach regarding the duration of treatment, with Peptamen Junior being used as a sole source of nutrition for 2 months, then being used as 1 meal per day (one third of nutrition) for 2 months. The minor submission stated that this was consistent with therapeutic guidelines for paediatric Crohn’s disease that recommends 6-8 weeks of exclusive enteral nutrition to induce remission.PSD · Mar 2020
Consumer comments
5.4 The NPWP had no concerns that the changes to formulation would pose a risk to the health and safety of patients and supported the request to change the formulation. For more detail on PBAC’s view, see section 6 PBAC outcome.PSD · Jul 2020
Cost-effectiveness
not-modelled; minor formulation change submission with no economic evaluation
The submission did not request a change of the price of Lipistart. PSD · 2020
Cost-effectiveness accepted ×3
Decision context
PopulationPatients with conditions requiring a source of medium chain triglycerides.
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Jul 2020 | Recommended · restricted | — | — | Cost-minimisation |
| Mar 2020 | Not recommended | standard enteral nutrition products (Ensure, PediaSure) | — | Single-arm · Other |
| Mar 2020 | Recommended · restricted | Monogen | — | Cost-minimisation · Cost-minimisation |
| Jul 2018 | Recommended | — | — | Cost-minimisation |
| Jul 2017 | Recommended | — | — | Cost-minimisation |
| Mar 2016 | Recommended · restricted | Peptamen Junior powder formula | — | Cost-minimisation · Cost-minimisation |
| Nov 2015 | Recommended | — | — | Other |
| Mar 2015 | Recommended · restricted | Peptamen Junior | — | Cost-minimisation · Cost-minimisation |
| Jul 2014 | Recommended · restricted | Monogen | — | Cost-minimisation · Cost-minimisation |
Consumer voice
No consumer comments were received for this item.
The PBAC noted that no consumer comments were received for this item. Consumer comments · PSD
Similar precedents
Medium Chain Triglycerides Formula90%Whey Protein Formula With Medium Chain Triglycerides, Carbohydrate, Vitamins And Minerals82%Medium Chain Triglycerides; Protein Formula With Carbohydrate, Fat, Vitamins And Minerals82%Protein Hydrolysate Formula With Medium Chain Triglycerides78%Triglycerides, Long Chain; Triglycerides, Medium Chain78%Triglycerides, Medium Chain77%Triglycerides, Medium Chain; Triglycerides, Long Chain76%Triglycerides Medium Chain And Long Chain With Glucose Polymer72%
Regulatory · TGA
Label narrower than PBS population — PBAC specifies disease-specific causes of fat malabsorption and named metabolic conditions; TGA label covers all fat malabsorption broadly.